Newswise — Alex A. Adjei, MD, PhD, has been appointed Senior Vice President of Clinical Research and Chair of the Department of Medicine at Roswell Park Cancer Institute (RPCI).
In his role as Senior Vice President for Clinical Research, Dr. Adjei will be responsible for expanding its phase I and thoracic oncology programs. As Chair of the Department of Medicine, Dr. Adjei will work to enhance clinical care and research at Roswell Park and to establish new clinical and research initiatives.
Dr. Adjei is a distinguished national leader in translational research, drug development and thoracic oncology. He comes to RPCI from the Mayo College of Medicine, Rochester, MN, where he served as Professor of Oncology and led highly successful thoracic oncology and phase I clinical research programs.
A native of Ghana, Dr. Adjei earned his medical degree from the University of Ghana Medical School in Legon. He obtained a doctorate degree in pharmacology at the University of Alberta in Edmonton, Canada. Dr. Adjei completed residency training at Howard University, Washington, DC, and clinical and research fellowships in oncology at Johns Hopkins School of Medicine, Baltimore, MD. He is a Diplomate of the American Board of Internal Medicine.
Dr. Adjei's research is focused on the development of novel agents for the therapy of solid tumors. In the clinic, his work has centered on the assessment of the toxicity, pharmacology and initial activity of selected agents and regiments in early clinical trials, and development of biomarkers of drug effects as well as phase II clinical trials of novel agents in lung cancer. In the laboratory, his interest is in the elucidation of mechanisms of action and resistance of novel agents that inhibit cell signaling.
Dr. Adjei is an active member of numerous professional organizations. As a member of the American Association for Cancer Research (AACR), he has served as Chair of the Minorities in Cancer Research Council; Co-Chair of the AACR's 2005 Annual meeting and currently is Co-Chairperson of the 2007 AACR Annual Meeting.
Dr. Adjei has served on many National Cancer Institute committees. He is Group Vice-Chair of the North Central Cancer Treatment Group (NCCTG) and Chair of the NCCTG Lung Cancer Committee. He was a member of the Lung Cancer Progress Review Group in 2000 and the Lung Cancer Concept Evaluating Panel from 1999-2002. He is a member of the Clinical Research Review Committee Study Section of the National Center for Research Resources for the National Institutes of Health, and the Investigational Drug Steering Committee, for which he co-chairs the Clinical Trials Design Task Force.
Dr. Adjei has served as a member of several editorial boards for scientific journals, including Senior Editor of Molecular Cancer Therapeutics, Associate Editor of American Journal of Clinical Oncology, Current Drug Targets, Investigational New Drugs and an editorial board member of the Journal of Clinical Oncology, Cancer Chemotherapy and Pharmacology, Clinical Lung Cancer, Medicinal Chemistry Reviews and Update on Cancer Therapeutics.
Roswell Park Cancer Institute, founded in 1898, is the nation's first cancer research, treatment and education center and is the only National Cancer Institute- designated comprehensive cancer center in Upstate New York. RPCI is a member of the prestigious National Comprehensive Cancer Network, an alliance of the nation's leading cancer centers. For more information, visit the RPCI website at http://www.roswellpark.org, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail [email protected].
RSS